(HealthDay)—Non-vitamin K oral anticoagulants (NOACs) have a superior benefit-risk profile to that of vitamin K antagonists (VKAs) for patients with
Continue reading »
Home »
Racial disparities seen in use of oral anticoagulants for A-fib
(HealthDay)—Black patients with atrial fibrillation are less likely to receive direct-acting oral anticoagulants (DOACs) compared with white patients, even after
Continue reading »